PMC:7572153 / 20228-21247 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7572153","sourcedb":"PMC","sourceid":"7572153","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7572153","text":"A more comprehensive comparison between our assay and the fully automated IgG CLIA was performed. First, we confirmed the high specificity of the CLIA assay with negative testing of 72 sera of the pre-COVID period. Additionally, 102 serum samples were analyzed for SARS-CoV-2-specific IgG side-by-side in the both assays revealing divergent results for three samples. These samples derived from convalescent patients were all positive in our assay and confirmed in the ELISA (2 positive, 1 borderline) but negative in the CLIA (data not shown). Overall, this demonstrates a high sensitivity of our cytometric antibody assay in a direct comparison to commercially available detection kits (Table 1). The lower detection limit was also confirmed by serial dilutions of selected positive samples. While 1–10,000 dilutions were still measured as seropositive by our flow cytometric assay, the two other kits revealed a negative result suggesting a higher analytical sensitivity of the flow cytometric test (data not shown).","tracks":[]}